Atossa Therapeutics, Inc. (ATOS)
Automate Your Wheel Strategy on ATOS
With Tiblio's Option Bot, you can configure your own wheel strategy including ATOS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ATOS
- Rev/Share 0.0
- Book/Share 0.5057
- PB 1.7061
- Debt/Equity 0.0
- CurrentRatio 12.6717
- ROIC -0.316
- MktCap 111447875.0
- FreeCF/Share -0.1727
- PFCF -4.9948
- PE -4.2305
- Debt/Assets 0.0
- DivYield 0
- ROE -0.3626
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 3
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Atossa Therapeutics to Present at the Jefferies Global Healthcare Conference
Published: June 02, 2025 by: PRNewsWire
Sentiment: Neutral
SEATTLE , June 2, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced that Dr. Steven Quay, M.D., Ph.D., President and Chief Executive Officer, will present at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025 at 7:35 a.m.
Read More
Join Atossa Therapeutics' Exclusive Live Investor Webinar and Q&A Session on May 22
Published: May 20, 2025 by: Accesswire
Sentiment: Neutral
SEATTLE, WASHINGTON / ACCESS Newswire / May 20, 2025 / Atossa Therapeutics, Inc. (Nasdaq:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, is pleased to invite investors to a webinar on May 22, 2025, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Dr. Steven Quay, CEO of Atossa Therapeutics.
Read More
Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year?
Published: May 15, 2025 by: Zacks Investment Research
Sentiment: Negative
Here is how Atossa Genetics Inc. (ATOS) and Clover Health Investments, Corp. (CLOV) have performed compared to their sector so far this year.
Read More
Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,281,056, Including 58 Claims Covering Various Formulations for its (Z)-endoxifen Portfolio
Published: April 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
SEATTLE, April 30, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced that the United States Patent and Trademark Office (USPTO) has granted a new patent (U.S. Patent No. 12,281,056) directed to highly pure and stable enteric oral formulations comprising (Z)-endoxifen as well as therapeutic methods of using those oral formulations.
Read More
Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,275,684, Further Strengthening (Z)-endoxifen Portfolio
Published: April 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
SEATTLE, April 22, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced that the United States Patent and Trademark Office (USPTO) has granted a new patent (U.S. Patent No. 12,275,684) directed to enteric oral formulations comprising (Z)-endoxifen as well as methods of treating subjects with those oral formulations.
Read More
All You Need to Know About Atossa Genetics (ATOS) Rating Upgrade to Buy
Published: March 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Atossa Genetics (ATOS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
Atossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update
Published: March 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
Ended 2024 with $71.1 million of cash and cash equivalents and no debt Conference Call and Webcast Scheduled for Tuesday, March 25, 2025, at 8:30 a.m. Eastern Time SEATTLE, March 25, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced its financial results for the full year ended December 31, 2024 and provided an update on recent company developments.
Read More
About Atossa Therapeutics, Inc. (ATOS)
- IPO Date 2012-11-08
- Website https://www.atossatherapeutics.com
- Industry Biotechnology
- CEO Dr. Steven C. Quay FCAP, M.D., Ph.D.
- Employees 15